dihydropyrimidine dehydrogenase deficiency, as a result of which they are unable to metabolize the 5-FU absorbed from the local application. [5, 8] Though punctal plugging is not routinely recommended for 5-FU eye drops [2] it may be advisable to apply pressure over the medial canthus after drop instillation to minimize systemic exposure.
Our patients probably had periocular skin exposure to 5-FU from the eye drops. These drops are routinely prepared in our hospital pharmacy and an error in drug concentration is not likely. Patients are also counseled that these are anticancer drugs and should be used strictly as per prescription. We did not find any similar reports in the ophthalmic literature. We would like to advise greater caution in the usage of 5-FU for ocular surface squamous neoplasia.
Conclusion
Ophthalmologists need to be aware of the rare possibility of serious skin reactions and the rare possibility of systemic side effects even with topical use.
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Case Reports
Xeroderma pigmentosum (XP) is a rare autosomal recessive inherited disorder characterized by deficiency of the enzymes responsible for repairing ultraviolet-radiation-induced DNA damage. [1] Persistence of unrepaired DNA damage results in somatic mutations, leading to neoplasia of the skin and ocular surface. Ocular surface squamous neoplasia (OSSN) and rarely conjunctival melanoma have been reported in patients with XP. However, simultaneous presentation of both malignancies in the same eye has not been reported.
Case Report
A 16-year-old previously diagnosed male patient with XP presented with chief complaint of slowly progressive, painless, nonpigmented and pigmented nodular opacities in the left eye noticed since the past 2 months. His parents had history of consanguineous marriage and his younger sibling was also diagnosed with XP. On general physical examination, he had hyperpigmented skin macules diffusely affecting the whole body. All data for this report are collected according to the Declaration of Helsinki, and prior permission was taken from the patient or parents for publication of photographs.
His best-corrected visual acuity (BCVA) in both eyes was 6/6. On slit-lamp examination, the right eye showed a pearly white plaque-like lesion at the temporal limbus measuring A clinical diagnosis of OSSN with primary acquired melanosis in the right eye and XP with OSSN and conjunctival melanoma in the left eye was made. There was no regional lymphadenopathy. Wide margin excision biopsy of both lesions along with alcohol-assisted keratoepitheliectomy and cryotherapy to conjunctival edges and amniotic membrane grafting was done in both eyes. On his second week postoperative follow-up, a 1 × 1 mm gelatinous nonpigmented nodule was noted at the edge of the excised conjunctival OSSN in the left eye [ Fig. 3a] . AS-OCT corresponding to the nodule revealed hyper-reflective thickened epithelium with abrupt transition suggestive of OSSN recurrence [Fig. 3b] . The patient was started on topical interferon alpha2b eye drops four times daily in the left eye. At 4 months of follow-up, the recurrent OSSN in the left eye had regressed completely. His ocular surface was stable in both eyes with minimal conjunctival scarring and inferior corneal scar in the left eye [ Fig. 3c and d] . No further recurrence of OSSN or conjunctival melanoma was noted at last follow-up visit.
Discussion
Oculocutaneous malignancies in XP mainly comprise basal cell carcinomas which are slow-growing and rarely metastasize and squamous cell carcinomas (SCC) which are fast-growing, invasive, and can metastasize.
[2] These malignancies are seen in 50% of the patients with XP in the first decade of life. Oculocutaneous SCC in XP has double (4%) metastatic potential compared with the non-XP-associated SCC (2%). [3] Conjunctival melanoma has been reported rarely in patients with XP.
Patients without XP present with nonmelanocytic oculocutaneous malignancies at a mean age of 67 years and oculocutaneous melanomas at 55 years. [4] However, in the patients with XP, the median age at diagnosis of nonmelanocytic oculocutaneous malignancies is 9 years (range 1-32 years) and oculocutaneous melanoma is 22 years (range 2-47 years). [5] In patients with XP, the inability to repair the ultraviolet-light-induced DNA damage leads to somatic mutations and the development of cancerous growth. This inherent defect, in turn, accounts for the increased susceptibility of such patients to OSSN at a younger age. [6] O S S N i n X P i s f r e q u e n t l y b i l a t e r a l , m o r e aggressive (recurrence rate = 64.3%) than usual, and the prognosis is poor when compared with the normal population. [7] This is evident in our case as well where the patient presented with OSSN recurrence in the early postoperative period despite tumor-free margins on histopathology.
Patients with XP can also develop melanocytic neoplasms of ocular surface, particularly seen in (but not limited to) UV-exposed areas. In a longitudinal study that evaluated ocular features in patients with XP, conjunctival melanosis was seen in 20% of patients and conjunctival melanoma in only 1 out of 87 patients with XP. [8] Uveal and orbital melanoma has also been reported in patients with XP. Two cases of malignant melanoma involving iris and ciliary body in patients with XP have been reported which necessitated enucleation in both patients. [9, 10] Primary orbital melanoma, including amelanotic variant, has also been reported in patients with XP. [11, 12] However, simultaneous occurrence of OSSN and conjunctival melanoma in patients with XP is reported rarely. Caso E R has recently reported a histopathology-confirmed OSSN in one eye and conjunctival melanoma in the other eye in an 18-year-old patient with XP. [13] Our patient adds to this literature evidence of melanocytic and nonmelanocytic conjunctival neoplasms developing simultaneously in patients with XP. In our patient, both OSSN and conjunctival melanoma were present simultaneously in one eye. This presentation was not reported earlier.
The management of ocular malignancy in a patient with XP should be focused on early detection. Detailed slip-lamp evaluation of ocular surface starting from early childhood and prompt biopsy of any suspicious lesion are required to prevent morbidity related to ocular surface tumors in these patients. Pigmented conjunctival lesions also need biopsy to rule out conjunctival melanoma or precursor lesions. Literature reports of the role of adjuvant topical therapy in these patients are scanty. However, high and early recurrence rate of OSSN in patients with XP as exemplified by our case emphasizes the need for close postoperative follow-up and possible role of topical adjuvant therapy with interferon alpha2b. Sun protection, long-sleeved clothing, scarfs, and sunglasses should be advised to all patients with XP to further minimize UV-radiation-induced DNA damage.
Conclusion
In conclusion, OSSN and conjunctival melanoma can coexist simultaneously in the same eye in patients with XP. All patients with XP should be thoroughly screened for OSSN and melanocytic conjunctival lesions, and prompt biopsy is indicated at earliest clinical suspicion Close postoperative follow-up is required to detect and treat tumor recurrence in these patients.
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